News
Amgen said on Monday its experimental cancer therapy significantly improved overall survival in patients with advanced ...
An addition to a Columbus factory is part of a planned $1B U.S. expansion for Central Ohio's second-largest manufacturer.
12h
Medpage Today on MSNThis Dietary Pattern Is Linked With Lower Crohn's Disease RiskIn a European study, higher consumption of fruits, vegetables, legumes, and potatoes was associated with a reduced risk of ...
Amgen plans to proceed with Phase 3 trials, initiating patients on a lower dosage that will gradually increase over an ...
StockStory.org on MSN5d
5 Insightful Analyst Questions From Amgen’s Q1 Earnings CallAmgen’s first quarter results reflected robust demand across its portfolio, with product volumes and sales increasing in both ...
Amgen's Phase 3 trial of bemarituzumab plus chemo met its survival goal in FGFR2b+ gastric cancer, with full data expected ...
Amgen & Zai Lab's trial shows bemarituzumab + chemo boosts survival in gastric cancer with FGFR2b. Read more here.
Back in 2021, Amgen picked up the phase 3-ready candidate in a $1.9 billion acquisition of Five Prime Therapeutics. The ...
In a detail-thin announcement, Amgen said that adding bemarituzumab to chemotherapy improved overall survival, though ...
US biotech major Amgen today announced the Phase III FORTITUDE-101 clinical trial evaluating first-line bemarituzumab plus ...
Amgen said a Phase 3 trial of its gastric cancer treatment, bemarituzumab, met its primary endpoint of overall survival at a pre-specified interim analysis.
Amgen Inc. (NASDAQ:AMGN) is one of the 11 stocks Jim Cramer put under the microscope recently. Cramer highlighted Wall Street ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results